

Clinical trials of vascular endothelial growth factor

TrialResults-center www.trialresultscenter.org

1 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
vascular endothelial growth factor vs placebo			
VIVA (Henry) , 2003 n=NA follow-up: 12 days	intracoronary and intravenous infusions of recombinant human vascular endothelial growth factor protein (rhVEGF) versus placebo	patients with stable exertional angina, unsuitable for standard revascularization	double blind

More details and results :

- cell-based therapies for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q300>

References

VIVA (Henry), 2003:

Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER Circulation 2003;107:1359-65 [[12642354](#)]